Differences in Tumor-Associated T cell receptor repertoires between Early-Onset and Average-Onset colorectal cancer.

Early Onset Colorectal Cancer T cell repertoire immune response tumor microenvironment

Journal

Journal of the National Cancer Institute
ISSN: 1460-2105
Titre abrégé: J Natl Cancer Inst
Pays: United States
ID NLM: 7503089

Informations de publication

Date de publication:
20 Jun 2024
Historique:
received: 24 01 2024
revised: 01 05 2024
accepted: 13 06 2024
medline: 21 6 2024
pubmed: 21 6 2024
entrez: 21 6 2024
Statut: aheadofprint

Résumé

The incidence of colorectal cancer (CRC) among individuals younger than age 50 (early onset CRC; EOCRC) has substantially increased, yet the etiology and molecular mechanisms underlying this alarming rise remain unclear. We compared tumor-associated T cell repertoires between EOCRC and average-onset CRC (AOCRC) to uncover potentially unique immune microenvironment-related features by age of onset. Our discovery cohort included 242 patients who underwent surgical resection at Cleveland Clinic from 2000 to 2020. EOCRC was defined as age < 50 years at diagnosis (N = 126), and AOCRC as age ≥ 60 years (N = 116). T cell receptor (TCR) abundance and clonality were measured by immunosequencing of tumors. Logistic regression models were used to evaluate the associations between TCR repertoire features and age of onset, adjusting for sex, race, tumor location, and stage. Findings were replicated in 152 EOCRC and 1,984 AOCRC cases from the Molecular Epidemiology of Colorectal Cancer Study. EOCRC tumors had significantly higher TCR diversity compared to AOCRC tumors in the discovery cohort (Odds Ratio (OR):0.44, 95% Confidence Interval (CI):0.32-0.61, p < .0001). This association was also observed in the replication cohort (OR : 0.74, 95% CI : 0.62-0.89, p = .0013). No significant differences in TCR abundance were observed between EOCRC and AOCRC in either cohort. Higher TCR diversity, suggesting a more diverse intratumoral T cell response, is more frequently observed in EOCRC than AOCRC. Further studies are warranted to investigate the role of T cell diversity and the adaptive immune response more broadly in the etiology and outcomes of EOCRC.

Identifiants

pubmed: 38902947
pii: 7696717
doi: 10.1093/jnci/djae143
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© The Author(s) 2024. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Auteurs

Ya-Yu Tsai (YY)

Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.

Kanika G Nair (KG)

Cleveland Clinic Center for Young-Onset Colorectal Cancer, Cleveland Clinic, Cleveland, OH, USA.
Department of Hematology and Oncology, Cleveland Clinic, Cleveland, OH, USA.

Shimoli V Barot (SV)

Cleveland Clinic Center for Young-Onset Colorectal Cancer, Cleveland Clinic, Cleveland, OH, USA.
Department of Hematology and Oncology, Cleveland Clinic, Cleveland, OH, USA.

Shao Xiang (S)

Department of Inflammation and Immunity, Cleveland Clinic, Cleveland, OH, USA.

Suneel Kamath (S)

Cleveland Clinic Center for Young-Onset Colorectal Cancer, Cleveland Clinic, Cleveland, OH, USA.
Department of Hematology and Oncology, Cleveland Clinic, Cleveland, OH, USA.
Case Comprehensive Cancer Center, Cleveland, OH, USA.
Cleveland Clinic Lerner College of Medicine, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.

Marilena Melas (M)

Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA.

Christopher P Walker (CP)

Department of Medical Oncology and Center for Precision Medicine, City of Hope National Medical Center, Duarte, CA, USA.

Raghvendra Srivastava (R)

Center for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic, Cleveland, OH, USA.

Nicole Osborne (N)

Center for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic, Cleveland, OH, USA.

Timothy A Chan (TA)

Center for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic, Cleveland, OH, USA.

Jonathan B Mitchem (JB)

Department of Colorectal Surgery, Cleveland Clinic, Cleveland, OH, USA.
VA Northeast Ohio Health System, Cleveland, OH, USA.
Department of Inflammation and Immunity, Cleveland Clinic, Cleveland, OH, USA.

Joseph D Bonner (JD)

Department of Medical Oncology and Center for Precision Medicine, City of Hope National Medical Center, Duarte, CA, USA.

Kevin J McDonnell (KJ)

Department of Medical Oncology and Center for Precision Medicine, City of Hope National Medical Center, Duarte, CA, USA.

Gregory E Idos (GE)

Department of Medical Oncology and Center for Precision Medicine, City of Hope National Medical Center, Duarte, CA, USA.

Rebeca Sanz-Pamplona (R)

Catalan Institute of Oncology (ICO), Hospitalet de Llobregat, Barcelona, Spain.
ONCOBELL Program, Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat, Barcelona, Spain.
Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Spain.
Hospital Universitario Lozano Blesa, Aragon Health Research Institute (IISA), ARAID Foundation, Aragon Government, Zaragoza, Spain.

Joel K Greenson (JK)

University of Michigan, Ann Arbor, MI, USA.

Hedy S Rennert (HS)

B. Rappaport Faculty of Medicine, Technion and the Association for Promotion of Research in Precision Medicine (APRPM), Haifa, Israel.

Gad Rennert (G)

B. Rappaport Faculty of Medicine, Technion and the Association for Promotion of Research in Precision Medicine (APRPM), Haifa, Israel.

Victor Moreno (V)

Catalan Institute of Oncology (ICO), Hospitalet de Llobregat, Barcelona, Spain.
ONCOBELL Program, Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat, Barcelona, Spain.
Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Spain.
Department of Clinical Sciences, Faculty of Medicine and Health Sciences and Universitat de Barcelona Institute of Complex Systems (UBICS), University of Barcelona, Barcelona, Spain.

Stephen B Gruber (SB)

Department of Medical Oncology and Center for Precision Medicine, City of Hope National Medical Center, Duarte, CA, USA.

Alok A Khorana (AA)

Cleveland Clinic Center for Young-Onset Colorectal Cancer, Cleveland Clinic, Cleveland, OH, USA.
Department of Hematology and Oncology, Cleveland Clinic, Cleveland, OH, USA.
Cleveland Clinic Lerner College of Medicine, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.

David Liska (D)

Cleveland Clinic Center for Young-Onset Colorectal Cancer, Cleveland Clinic, Cleveland, OH, USA.
Department of Inflammation and Immunity, Cleveland Clinic, Cleveland, OH, USA.
Department of Colorectal Surgery, Cleveland Clinic, Cleveland, OH, USA.
Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.

Stephanie L Schmit (SL)

Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
Department of Inflammation and Immunity, Cleveland Clinic, Cleveland, OH, USA.
Population and Cancer Prevention Program, Case Comprehensive Cancer Center, Cleveland, OH, USA.

Classifications MeSH